Gain Therapeutics, Inc. (GANX)
Fuera de horario:
Gain Therapeutics, Inc.
4800 Montgomery Lane
Suite 220
Bethesda, MD 20814
United States
301 500 1556
https://www.gaintherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 29
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Khalid Islam Ph.D. | Founder & Chairman | 75k | N/D | 1955 |
| Mr. Matthias Alder LIC. IUR., LL.M. | President, CEO & Director | 669.44k | N/D | 1965 |
| Mr. Gene Mack M.B.A. | Chief Financial Officer | N/D | N/D | N/D |
| Dr. Joanne Taylor Ph.D. | Senior Vice President of Research | N/D | N/D | N/D |
| Dr. Terenzio Ignoni Pharm.D. | Senior Vice President of Technical Operations | N/D | N/D | N/D |
| Dr. Jonas Hannestad M.D., Ph.D. | Chief Medical Officer | N/D | N/D | N/D |
Descripción
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland.
Gestión corporativa
La calificación ISS Governance QuickScore de Gain Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
